Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1129-1140, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hammett-Stabler, C. A.
Right arrow Articles by Johns, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hammett-Stabler, C. A.
Right arrow Articles by Johns, T.
Related Collections
Right arrow National Academy of Clinical Biochemistry
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1998;44:1129-1140.)
© 1998 American Association for Clinical Chemistry, Inc.

NACB Symposium

Laboratory guidelines for monitoring of antimicrobial drugs

Catherine A. Hammett-Stablera, and Thomas Johns

Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine; and College of Pharmacy, Gainesville, FL 32610.
a Address correspondence to this author at: Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Box 100275, Gainesville, FL 32610. Fax 352-395-0585; e-mail stabler.pathology{at}mail.health.ufl.edu.

Few antimicrobial drugs meet the requirements for therapeutic drug monitoring. Those that are monitored include the aminoglycosides (gentamicin, tobramycin, and amikacin), chloramphenicol, and in some cases, vancomycin. For these drugs, there is evidence of a relationship between serum concentration, efficacy, and/or the incidence of adverse or toxic events. Monitoring begins with the appropriate timing of collection and continues through the analytical process to the integration of all data used to guide the clinician's next decision.




The following articles in journals at HighWire Press have cited this article:


Home page
 J Antimicrob ChemotherHome page
D. L. MacLeod, L. M. Barker, J. L. Sutherland, S. C. Moss, J. L. Gurgel, T. F. Kenney, J. L. Burns, and W. R. Baker
Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis
J. Antimicrob. Chemother., October 1, 2009; 64(4): 829 - 836.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. A. Simons, A. R. Molinelli, K. Sobhani, P. M. Rainey, and A. N. Hoofnagle
Two Cases with Unusual Vancomycin Measurements
Clin. Chem., March 1, 2009; 55(3): 578 - 580.
[Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
A Mohammadi-Karakani, S Asgharzadeh-Haghighi, M Ghazi-Khansari, A Seyed-Ebrahimi, A Ghasemi, and E Jabari
Enzymuria determination in children treated with aminoglycosides drugs
Human and Experimental Toxicology, December 1, 2008; 27(12): 879 - 882.
[Abstract] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
O Plan, G Cambonie, E Barbotte, P Meyer, C Devine, C Milesi, O Pidoux, M Badr, and J C Picaud
Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2008; 93(6): F418 - F421.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R K Crowley, F Fitzpatrick, D Solanki, S FitzGerald, H Humphreys, and E G Smyth
Vancomycin administration: the impact of multidisciplinary interventions
J. Clin. Pathol., October 1, 2007; 60(10): 1155 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C.-H. Li, S.-L. Tzeng, Y.-W. Cheng, and J.-J. Kang
Chloramphenicol-induced Mitochondrial Stress Increases p21 Expression and Prevents Cell Apoptosis through a p21-dependent Pathway
J. Biol. Chem., July 15, 2005; 280(28): 26193 - 26199.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Schiffelers, G. Storm, and I. Bakker-Woudenberg
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies
J. Antimicrob. Chemother., September 1, 2001; 48(3): 333 - 344.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.